Joe Wiley, Amryt CEO
After being ushered onto the inside lane at FDA, regulators hand Amryt a CRL for rare disease drug
Amryt may have earned a priority review for its drug to treat rare cases of epidermolysis bullosa (EB), but they got handed a CRL for …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
